Genetic factors play a critical role in the pathogenesis of vascular anomalies. Significant advances have been made in recent years in identifying the genetic and molecular determinants of a variety of vascular anomalies using a molecular genetic approach. Several genes for vascular anomalies have been identified. These genes include AGGF1 for Klippel-Trenaunay syndrome, RASA1 for capillary malformations, KRIT1, MGC4607, PDCD10 for cerebral cavernous malformations, glomulin for glomuvenous malformations, TIE2 for multiple cutaneous and mucosal venous malformations, VEGFR-3, FOXC2, NEMO, SOX18 for lymphedema or related syndromes, ENG, ACVRLK1, MADH4 for HHT or related syndromes, NDP for Coats' disease, Notch3 for CADASIL, and PTEN for Proteus Syndrome. These findings have made genetic testing possible in some clinical cases, and may lead to the development of therapeutic strategies for vascular anomalies. Furthermore, these studies have identified critical genes involved in vascular morphogenesis, and provided fundamental understanding of the molecular mechanisms underlying vasculogenesis and angiogenesis.
malformations, telangiectasia, and combined or mixed vascular malformations. Vascular malformations are usually present at birth, grow proportionally with the patient, and rarely regress.
Little is known about the genetics of hemangiomas except that a locus was reported on chromosome 5q31-35. 4 In addition, one somatic mutation P1147S in VEGFR2, a receptor for angiogenic factor VEGF, and another mutation P954S in VEGFR3 were reported, 5 but the link between these two mutations and the disease remains to be established. In contrast, molecular genetic studies have identified disease-causing genes for a variety of vascular malformations ( Table 1) . The vascular anomaly genes identified before 2003 have been reviewed previously in this journal by Chaft et al. 6 Here, the author updates the advances made in this field.
GENETICS OF CEREBRAL CAVERNOUS MALFORMATIONS (CCM)
Cerebral cavernous malformations (CCM, MIM #116860) are vascular malformations of the central nervous system. Some cases of CCM are asymptomatic, but others can cause seizures, hemorrhagic stroke, or focal neurological deficit. CCM can occur in a sporadic form as well as a familial form. 7 Familial CCM are inherited in the autosomal dominant mode, and three genes have been localized to chromosome 7q11.2-21 (CCM1, MIM *604214), 7p15-13 (CCM2, #MIM 603284), and 3q25.2-27 (CCM3, MIM #603285).
The disease-causing gene for CCM1 has been identified as KRIT1 (Krev interaction trapped 1), 8,9 which encodes a protein with a four ankyrin repeat domain at the N-terminus and a Cterminal domain for interaction with Krev-1 (Rap1a, ras-related protein 1A). Many KRIT1 mutations have been identified in patients with CCM and most of them are loss-of-function mutations. Approximately 40% of CCM families carry KRIT1 mutations. The N-terminus of KRIT1 also contains an NPXY motif that has been recently shown to interact with ICAP1α, the integrin cytoplasmic domain-associated protein-1α. 10 This interaction competes directly with an interaction between a NPXY motif in the cytoplasmic domain of β1 integrin and ICAP1α 10 . Loss-of function mutations in KRIT1 are expected to lead to increased interaction between ICAP1α and β1 integrin, which influences integrin β1-dependent cell adhesion, migration, and angiogenesis.
The second CCM gene, CCM2, has been identified as a novel gene called MGC4607 by two independent groups. 11,12 The function of MGC4607 is unknown except that it contains a phosphotyrosine-binding or PTB domain. 11,12 MGC4607 mutations may account for 20% of familial CCM cases.
The CCM3 gene has been identified as PDCD10 (programmed cell death 10, TFAR15). 13 Approximately 40% of CCM families are linked to the CCM3 locus. PDCD10 was initially identified as a gene whose expression was up-regulated in the TF-1 premyeloid cell line after growth factor deprivation and in a fibroblast cell line upon apoptosis induction. 14 Its role in vascular morphogenesis remains to be investigated.
GENETICS OF HEREDITARY HEMORRHAGIC TELANGIECTASIA (HHT)
Hereditary hemorrhagic telangiectasia (HHT, MIM #187300) is an autosomal dominant vascular dysplasia characterized by mucocutaneous telangiectases and arteriovenous malformations of skin, mucosa, and viscera (lung, liver, and brain). The frequent complications are epistaxis and gastrointestinal haemorrhage. Previous genetic linkage analysis has identified two loci, HHT1 on chromosome 9q34.1 (MIM #187300) and HHT2 on chromosome 12q11-14 (MIM #600376). HHT1 is caused by mutations in endoglin which encodes a TGFβ binding protein expressed predominantly in endothelial cells. 15 Endoglin binds to TGFβ1, TGFβ2, activin-A, BMP2, and BMP7, but not to TGFβ2. 16, 17 Endoglin is involved in the TGFβ signaling pathway, which lays an important role in vascular remodeling and the maintenance of vessel wall integrity. 18 HHT2 results from mutations in the ALK1 or ACVRL1 gene which encodes a type 1 serine-threonine kinase receptor in endothelial cells. 19 ALK1 binds to TGFβ1 and activin-A, and signal through phosphorylation of SMAD1 and SMAD5. 20,21 HHT patients with mutations in endoglin are associated with a more severe clinical outcome, an earlier onset of epistaxis and telangiectasis, than those with ALK1 mutations. 22 Pulmonary arteriovenous malformations were detected only in patients with endoglin mutations in a cohort study of 49 HHT1 patients and 34 HHT2 patients. 22 Recently, the third genetic locus for HHT, HHT3, was identified. Cole et al. 23 studied a family in which linkage to endoglin, ALK1, and SMAD4 was excluded. A genome-wide scan of the family identified linkage to markers on chromosome 5q31.5-32. 23 The specific HHT gene at this locus has not been identified yet.
HHT associated with juvenile polyposis (JP) has been found to be a distinct syndrome, JP/ HHT (MIM #175050). Familial JP can be caused by mutations in the MADH4 gene on chromosome 18q21.1 which encodes SMAD4. 24 Interestingly, Gallione et al. 24 identified MADH4 mutations in six unrelated families segregating both JP and HHT. SMAD4 is an integral downstream effector of the TGFβ signal transduction pathway.
Another telangiectasia related disease, Coats' disease or retinal telangiectasis (MIM, #300216) is characterized by a defect of retinal vascular development that results in vessel leakage, subretinal exudation, and retinal detachment. Retinal telangiectasis was found to be associated with a somatic mutation in the Norrie disease gene NDP on chromosome Xp11.4. 25 NDP encodes a protein called norrin, a secreted protein that can bind to receptor Frizzled-4 (Fz4), which may activate a signaling pathway involved in vascular development in the eye and ear.
GENETICS OF KLIPPEL-TRENAUNAY SYNDROME
Klippel-Trenaunay syndrome (KTS, MIM #149000) is a congenital vascular disorder comprised of capillary malformations (98% of KTS patients), venous malformations or varicose veins (72% of patients), and hypertrophy of the affected tissues (67% of the patients), but the presence of two of the three cardinal features is sufficient to make a diagnosis. 26 Most KTS cases are sporadic. Interestingly, three chromosomal abnormalities have been reported in three different KTS patients: two balanced translocations t(5;11)(q13.3;p15.1) and t(8;14) (q22.3;q13), and an extra supernumerary ring chromosome 18 1,27-29 . Translocation t(8;14) (q22.3;q13) and the ring chromosome 18 were shown to arise de novo, which strongly suggests that genetic factors contribute to the pathogenesis of KTS. Characterization of cytogenetic abnormalities such as translocations associated with diseases is a very useful approach to identify human disease genes. For translocation t(8;14)(q22.3;q13), the breakpoint on chromosome 8q22.3 has been defined to a <5-cM interval, and the 14q13 breakpoint within a 1-cM region. 29 The specific vascular gene disrupted by either 8q22.3 or 14q13 breakpoints remains to be identified. The ring chromosome 18 r(18) was mostly derived from the short arm of chromosome 18, and further analyses of the genes on the r(18) may lead to the identification of a vascular gene. 28
Chromosomal breakpoints involved in translocation t(5;11)(q13.3;p15.1) have been fully characterized, which has led to the identification of a susceptibility gene, AGGF1 (previously known as VG5Q), for KTS. 27 AGGF1 is located on chromosome 5q13.3 and encodes an angiogenic factor. 27 AGGF1 protein contains a coiled-coil motif (amino acids 19-85), an OCRE (OCtamer REpeat) motif (amino acids 197-256), a forkhead-associated domain (FHA, amino acids 435 to 508) and a G-patch domain (amino acids 619-663), but the exact function of each domain remains to be defined. The chromosome 5q13.3 breakpoint is located in the promoter region of AGGF1, and increases the expression of AGGF1 by three-fold. 27 A mutation, E133K, in AGGF1 was identified and was later shown to increase the angiogenic activity of AGGF1. Mutation E133K was established to be associated with KTS using a casecontrol association study (the frequency of allele K, 3.8% in cases vs. 0% in controls, P = 0.009). These results establish AGGF1 as the first susceptibility gene that confers a risk to the development of KTS, and suggest that that the molecular mechanism for the pathogenesis of KTS is the "increased" angiogenesis. These results are consistent with histological studies that showed an increase in both the number and diameter of the venules in the dermis and subdermal fat of KTS tissues. 30
Sporadic occurrence of KTS and a mosaic pattern of KTS features may be explained by the two-hit hypothesis and the concept of paradominant inheritance proposed by Happle. 31-33 Germline mutations in a KTS gene (e.g., AGGF1) are important for development of KTS, but not sufficient. A "second hit", somatic mutation in the same KTS gene or in a different gene is required for the development of KTS features.
GENETICS OF LYMPHEDEMA
Hereditary lymphedema (MIM #153100) is characterized by chronic swelling of the extremities by insufficient lymphatic drainage, and is caused by defects in lymphatic vessels, either hypoplasic or hyperplasic. The most common mode of inheritance for hereditary lymphedema is autosomal dominant. The first genetic locus for hereditary lymphedema was mapped to chromosome 5q35, and the disease-causing gene was subsequently identified as the FLT4 gene which encodes the vascular endothelial growth factor receptor-3, VEGFR3. 34, 35 Hereditary lymphedema associated with VEGFR3 mutations or type I hereditary lymphedema is an early-onset lymphedema that is usually present at birth or soon after birth.
The type II hereditary lymphedema (MIM #153200 and #602402) is a late-onset disease with reduced penetrance, variable phenotype, and association with other features including distichiasis, ptosis, cleft palate, yellow nails, and congenital heart disease. It is caused by mutations in the forkhead family transcription factor gene MFH1 (FOXC2) on chromosome 16q24.3. 36-38
The hypotrichosis-lymphedema-telangiectasia syndrome (HLTS, MIM #607823) is an interesting syndrome of combination of lymphedema with hypotrichosis (sparse hair) and telangiectasia (abnormal dilation of capillaries and arterioles). HLTS is caused by inactivating mutations in the SOX18 gene which is on chromosome 20q13 and encodes a transcription factor in the SOX (Sry-type high-mobility group box) family of transcription factors. 39 Three HLTS families with SOX18 mutations were reported; two families with a recessive mode of inheritance have homozygous missense mutations, and the one with autosomal dominant HLTS has a nonsense mutation (C240X) that generates a truncated SOX18 protein lacking the transactivation domain.
A rare X-linked recessive syndrome of anhidrotic ectodermal dysplasia with immunodeficiency, osteopetrosis, and lymphedema (OL-EDA-ID, MIM #300301) is caused by stop codon mutations in the NEMO gene on chromosome Xq28. 40 NEMO encodes the regulatory subunit of the IKK (IkappaB kinase) complex, which is essential for NF-kappaB signaling.
An autosomal recessive syndrome of hereditary recurrent cholestasis and lymphedema (MIM %214900) was reported and a genetic locus was identified on chromosome 15q. 41 The specific gene remains to be identified.
GENETICS OF CAPILLARY MALFORMATIONS
Capillary malformations (CM) or port-wine stains (MIM #163000) are the most common cutaneous vascular malformation that appears as a red macular stain. A genetic locus for CM, CMC1, was mapped to chromosome 5q14-21 in a study of 13 families. 42 Subsequent studies identified the CMC1 gene as the RASA1 gene which encodes p120-RasGTPase-activating protein (p120-RasGAP). RASA1 mutations were detected in families with capillary malformations associated with either arteriovenous malformation, arteriovenous fistula, or Parkes Weber syndrome (capillary malformation-arteriovenous malformation, CMAVM)" (MIM #608354). 43 The function of p120-Ras-GAP is to switch the active GTPbound Ras to the inactive GDP-bound form. Similar to KRIT that causes CCM1 when mutated, p120-Ras-GAP was shown to bind to Krev-1/Rap1a, 44 which is involved in integrin β1-mediated cell adhesion and angiogenesis.
GENETICS OF VENOUS MALFORMATIONS
Venous malformation is a common type of vascular anomaly. Two genes have been identified for venous malformations, TIE2 for mucocutaneous venous malformations (MIM #600195) and glomulin for glomuvenous malformations (MIM #138000). A linkage study of a three generation family with multiple cutaneous and mucosal venous malformations mapped the genetic locus to chromosome 9p21. 45 . The disease-causing gene was later identified as TIE2 that codes for the endothelial cell-specific receptor tyrosine kinase TIE2, which is a receptor for angiogenic factors angiopoietin-1 (Ang-1) and angiopoietin-2.
Glomuvenous malformations or glomangiomas are venous malformations with smooth muscle-like glomus cells (GVM, MIM #138000). Boon et al. 46 identified the first locus for GVM on chromosome 1p22-p21. The specific gene was later identified as the glomulin (FAP48) gene coding for an FK506-binding protein (FKBP)-associated protein of 48 kD. 47 The function of glomulin is unknown.
GENETICS OF CADASIL
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy (CADASIL, MIM #125310) is an inherited cerebrovascular disease characterized by recurrent transient ischemic attacks, strokes, vascular dementia, cognitive deficits, migraine, and psychiatric disorders. Patients with CADASIL show accumulation of electron dense granules (GOM) in the media of arterioles, and extensive cerebral white matter lesions and subcortical infarcts can be detected by MRI. CADASIL is caused by mutations in the Notch3 gene in the chromosome 19p13 region. 48 The mechanism by which Notch3 mutations cause CADASIL is not clear. Expression of Notch3 is highly restricted to vascular smooth muscle cells (VSMC), and is required to generate functional arteries by regulating arterial differentiation and maturation of VSMC. 49
GENETICS OF PROTEUS SYNDROME
Proteus syndrome (PS, MIM #176920) is a complex hamartomatous disorder which is characterized by connective tissue nevi, epidermal nevi, dysregulated adipose tissue, local overgrowth (macrocephaly, gigantism of hands and feet), subcutaneous tumors, and various vascular anomalies. 50 Common vascular anomalies in PS include vascular tumors, capillary malformations, and venous anomalies (varicosities, prominent veins). 50 About 20% of PS cases and 50% of patients with proteus-like syndrome (PSL) were found to carry germline mutations in the tumor suppressor gene PTEN on chromosome 10q23.3. 51 The PTEN gene codes for a lipid phosphatase that mediates cell cycle arrest and apoptosis, and is also a gene responsible for other diseases including 80% of classic Cowden syndrome (CS), and 60% of Bannayan-Riley-Ruvalcaba syndrome (BRRS). 51
SUMMARY
Molecular genetics has been demonstrated to be a powerful approach for dissecting the etiology of a variety of vascular anomalies. It has provided important insights into the pathogenic mechanisms of many vascular anomalies as well as the molecular mechanisms underlying vascular morphogenesis, growth, and development. A susceptibility gene has been identified for KTS, and disease-causing genes have been identified for cerebral cavernous malformations, HHT, Coats' disease, lymphedema, capillary malformations, multiple cutaneous and mucosal venous malformations, glomuvenous malformations, CADASIL, and Proteus syndrome (see Table 1 ). Genetic testing is now possible for many patients and/or families with vascular anomalies, which allows more accurate diagnosis and classification of vascular malformations. However, many new genes for vascular anomalies remain to be identified. The future research in the field will focus on (i) identification of new genes for vascular anomalies, (ii) functional characterization of vascular anomaly genes to probe the molecular mechanisms involved in vascular morphogenesis/growth/development, and the pathogenesis of each disease, and (iii) genotype-phenotype correlation studies and other translational studies that will help patients directly. These studies promise to revolutionize vascular medicine, improving the diagnosis and treatment of vascular anomalies. Table 1 Genetics of Vascular Anomalies 
